HaleonHLN
Market Cap: $47.9B
About: Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Employees: 24,622
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
105% more call options, than puts
Call options by funds: $476K | Put options by funds: $232K
22% more repeat investments, than reductions
Existing positions increased: 214 | Existing positions reduced: 175
0.07% more ownership
Funds ownership: 5.62% [Q1] → 5.69% (+0.07%) [Q2]
2% less capital invested
Capital invested by funds: $4.36B [Q1] → $4.29B (-$72.8M) [Q2]
4% less funds holding
Funds holding: 588 [Q1] → 564 (-24) [Q2]
31% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 78
75% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 1 (-3) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Rashad Kawan 100% 1-year accuracy 3 / 3 met price target | 4%upside $10.95 | Overweight Maintained | 20 Sept 2024 |
Financial journalist opinion
Based on 3 articles about HLN published over the past 30 days